Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q28371022)
Watch
English
NRAS Q61
genetic variant
Q61
GLN61
In more languages
edit
Statements
instance of
missense mutation
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/94
chromosome
human chromosome 1
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/94
genomic start
115256528
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/94
genomic end
115256530
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/94
biological variant of
NRAS
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/94
positive therapeutic predictor for
binimetinib
medical condition treated
skin melanoma
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1226
stated in
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
negative therapeutic predictor for
vemurafenib
determination method
CIViC evidence level B
rating
CIViC 4-star trust rating
medical condition treated
melanoma
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/14
stated in
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
cetuximab
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
colorectal cancer
statement disputed by
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/124
stated in
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
cetuximab / chemotherapy combination therapy
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
medical condition treated
colorectal cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/36
stated in
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
positive diagnostic predictor for
melanoma
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/10
stated in
NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
negative prognostic predictor for
follicular thyroid cancer
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
statement disputed by
Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/6959
stated in
Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.
Identifiers
CIViC variant ID
94
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/94
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
